A Single-arm, Single-center, Prospective Clinical Study of Adebelimab Combined With Chemotherapy for First-line Treatment of Sequential Adebelimab Plus Apatinib Maintenance Therapy in Patients With Extensive-stage Small Cell Lung Cancer

A study of adebelimab in combination with chemotherapy in the first-line treatment of extensive-stage small cell lung cancer

Start Date01 Feb 2025

Sponsor / Collaborator

Fujian Cancer Hospital

NCT06735508 / Not yet recruitingEarly Phase 1IIT

An Exploratory Study of the Personalized MRNA Neoantigen Vaccine in Combination with Adebrelimab As Adjuvant Treatment for Patients with Resected Non-small Cell Lung Cancer

Brief Summary: This study is an open, prospective, exploratory clinical trial designed to evaluate the safety,ability, immunogenicity, and preliminary efficacy of a personalized neoantigen mRNA vaccine in combination with adebelimab as adjuvant treatment for patients with non-small cell lung cancer (NSCLC).
The primary objectives of this study are to answer the following key questions:
1. The incidence of dose-limiting toxicities (DLTs) during the designated observation period.
2. The incidence and severity of adverse events (AEs) and serious adverse events (SAEs).
3. The determination of the maximum tolerated dose (MTD) or maximum administered dose (MAD).

Start Date01 Jan 2025

Sponsor / Collaborator

Guangdong General Hospital

[+1]

NCT06538935 / Not yet recruitingPhase 2IIT

A Phase II, Open-label, Two Arm, Investigator-initiated Trail of Stereotactic Radiotherapy (SBRT) in Combination With an Anti-PD-L1 Inhibitor Adbelimumab and Apatinib for Perioperative and Conversion Therapy of Hepatocellular Carcinoma

This is a Phase II , Open-label , Investigator-initiated Trail of SBRT in Combination With Adbelimumab and Apatinib in Patients With Hepatocellular Carcinoma(HCC).This study aims to evaluate the safety and efficacy of SBRT in Combination With Adbelimumab and Apatinib as a preoperative and conversion treatment of HCC.

Start Date01 Jan 2025

Sponsor / Collaborator

Fujian Cancer Hospital

100 Clinical Results associated with Adebrelimab

100 Translational Medicine associated with Adebrelimab

100 Patents (Medical) associated with Adebrelimab

Literatures (Medical) associated with Adebrelimab

31 Dec 2024·mAbs

Antibodies to watch in 2024

Article

Author: Crescioli, Silvia ; Kaplon, Hélène ; Wang, Lin ; Reichert, Janice M. ; Visweswaraiah, Jyothsna ; Chenoweth, Alicia

The 'Antibodies to Watch' article series provides an annual summary of commercially sponsored monoclonal antibody therapeutics currently in late-stage clinical development, regulatory review, and those recently granted a first approval in any country. In this installment, we discuss key details for 16 antibody therapeutics granted a first approval in 2023, as of November 17 (lecanemab (Leqembi), rozanolixizumab (RYSTIGGO), pozelimab (VEOPOZ), mirikizumab (Omvoh), talquetamab (Talvey), elranatamab (Elrexfio), epcoritamab (EPKINLY), glofitamab (COLUMVI), retifanlimab (Zynyz), concizumab (Alhemo), lebrikizumab (EBGLYSS), tafolecimab (SINTBILO), narlumosbart (Jinlitai), zuberitamab (Enrexib), adebrelimab (Arelili), and divozilimab (Ivlizi)). We briefly review 26 product candidates for which marketing applications are under consideration in at least one country or region, and 23 investigational antibody therapeutics that are forecast to enter regulatory review by the end of 2024 based on company disclosures. These nearly 50 product candidates include numerous innovative bispecific antibodies, such as odronextamab, ivonescimab, linvoseltamab, zenocutuzumab, and erfonrilimab, and antibody-drug conjugates, such as trastuzumab botidotin, patritumab deruxtecan, datopotamab deruxtecan, and MRG002, as well as a mixture of two immunocytokines (bifikafusp alfa and onfekafusp alfa). We also discuss clinical phase transition and overall approval success rates for antibody therapeutics, which are crucial to the biopharmaceutical industry because these rates inform decisions about resource allocation. Our analyses indicate that these molecules have approval success rates in the range of 14-32%, with higher rates associated with antibodies developed for non-cancer indications. Overall, our data suggest that antibody therapeutic development efforts by the biopharmaceutical industry are robust and increasingly successful.

01 Sep 2024·EClinicalMedicine

Adebrelimab plus chemotherapy and sequential thoracic radiotherapy as first-line therapy for extensive-stage small–cell lung cancer (ES-SCLC): a phase II trial

Article

Author: Tang, Xiaoyong ; Li, Butuo ; Meng, Xiangjiao ; Zhao, Changhong ; Zhu, Changbin ; Huang, Wei ; Chen, Dawei ; Guo, Jun ; Yuan, Jiajia ; Li, Qian ; Zhang, Yan ; Zhang, Pinliang ; Wang, Linlin ; Zou, Bing ; Shao, Qian ; Yu, Jinming ; Gao, Aiqin ; Hu, Xudong

Background:

This phase II prospective trial aimed to investigate the efficacy and safety of adebrelimab (PD-L1 antibody) plus first-line chemotherapy followed by sequential thoracic radiotherapy (TRT) combined with adebrelimab in extensive-stage small-cell lung cancer (ES-SCLC). Biomarkers associated with potential therapeutic effects were also explored.

Methods:

Patients with previously untreated ES-SCLC were enrolled at Shandong Cancer Hospital and Institute (Jinan, China). Patients received 4-6 cycles of adebrelimab (20 mg/kg, D1, Q3W) combined with EP/EC (etoposide, 100 mg/m², D1-3, Q3W and cisplatin, 75 mg/m², D1, Q3W or carboplatin, AUC = 5, D1, Q3W). Then patients with response sequentially underwent consolidative TRT (≥30 Gy in 10 fractions or ≥50 Gy in 25 fractions, involved-field irradiation), and maintenance adebrelimab until disease progression or intolerable adverse events (AEs). The primary endpoint was overall survival (OS). Genomic and circulating tumour DNA (ctDNA) profiling were also analyzed with tumour tissues and peripheral blood. This trial was registered with ClinicalTrials.gov, NCT04562337.

Findings:

From October 2020 to April 2023, 67 patients diagnosed with ES-SCLC were enrolled and received at least one dose of study treatment. All patients were included in the efficacy and safety analyses. 45 patients received sequential TRT as planned. The median OS and progression-free survival (PFS) was 21.4 months (95% CI: 17.2-not reached months) and 10.1 months (95% CI: 6.9-15.5 months), respectively. The confirmed objective response rate was 71.6% (48/67, 95% CI: 59.3-82.0%) and disease control rate was 89.6% (60/67, 95% CI: 79.7-95.7%). There were no treatment-related deaths. The most common grade 3 or higher treatment-related adverse events (TRAEs) were hematological toxicities. The incidence of any grade and G3+ pneumonitis was 25% (17/67) and 6% (4/67), respectively. No unexpected adverse events were observed. Patients without co-mutations of TP53/RB1 in both tissue and peripheral blood displayed longer PFS (tissue, P = 0.071; ctDNA, P = 0.060) and OS (tissue, P = 0.032; ctDNA, P = 0.031).

Interpretation:

Adebrelimab plus chemotherapy and sequential TRT as first-line therapy for ES-SCLC showed promising efficacy and acceptable safety.

Funding:

This study was funded by the National Natural Science Foundation of China (82172865), Jiangsu Hengrui Pharmaceuticals Co., Ltd. and Amoy Diagnostics Co., Ltd.

01 Jul 2024·CPT-Pharmacometrics & Systems Pharmacology

Population pharmacokinetics of adebrelimab – Support of alternative flat dose regimen in extensive‐stage small‐cell lung cancer

Article

Author: Wang, Yike ; Djebli, Nassim ; Ma, Ke ; Chen, Peng ; Zhang, Yanyan ; Shen, Kai ; Shi, Wei

Abstract:

Adebrelimab, a novel anti‐PD‐L1 antibody, has been approved by the National Medical Products Administration of China as an intravenous infusion for use in combination with carboplatin and etoposide as first‐line treatment for extensive‐stage small‐cell lung cancer in 2023. A two‐compartment model with empirical time‐varying CL for adebrelimab was established based on data from 263 patients receiving body weight‐based doses from two clinical studies. Significant covariate effects of baseline body weight, albumin levels, tumor size, neutrophil counts, and presence of anti‐drug antibodies were identified on CL of debrelimab, none of which were clinically significant or warranted dose adjustment. The degree of decrease in CL was higher in patients who responded to treatment with adebrelimab than in non‐responders. Adebrelimab exposures (AUC, Ctrough, or Cmax) were not identified as a statistically significant factor related to efficacy or safety endpoint in the exposure–response analysis. Distribution of simulated exposure metrics from the flat dose regimen (1200 mg q3w) was similar to the marketed weight‐based dosing regimen (20 mg/kg q3w), supporting the alternative flat dose regimen in the clinic.

News (Medical) associated with Adebrelimab

24 May 2024

·www.globenewswire.com

HUTCHMED Highlights Presentations at the 2024 ASCO Annual Meeting

HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., May 23, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that new and updated data from several studies of compounds discovered by HUTCHMED will be presented at the upcoming American Society of Clinical Oncology (“ASCO”) Annual Meeting, taking place May 31 – June 4, 2024 in Chicago, IL and online. Results will be presented from the registration Phase II study of fruquintinib combined with sintilimab in 98 second-line or above patients with endometrial cancer (“EMC”) with pMMR status by central laboratory analysis, which supported the New Drug Application (NDA) filed in China. The primary endpoint was objective response rate (“ORR”) per RECIST v1.1, assessed by an independent review committee. The combination showed meaningful efficacy improvements in advanced EMC patients with pMMR status, regardless of prior bevacizumab treatment, with a manageable safety profile. The median follow-up time was 15.7 months. The ORR in 87 efficacy evaluable patients was 35.6% including two complete responses. Disease control rate (“DCR”) was 88.5%, and duration of response was not reached, with 80.7% remaining in response after nine months. Amongst the 98 patients, median progression-free survival (PFS) was 9.5 months, and median overall survival (OS) was 21.3 months. Further details are available in the abstract link below. Following the initial data of the FRUTIGA Phase III study of fruquintinib in second-line gastric cancer published during the February 2024 ASCO Plenary Series session, further updated efficacy data in key subgroups, and quality of life data will be presented at this year’s ASCO annual meeting. In addition, further data from the FRESCO and FRESCO-2 Phase III colorectal cancer studies, the study of surufatinib combinations in small cell lung cancer, and initial clinical data for the ERK1/2 inhibitor HMPL-295 will be presented. Details of the presentations, including links to available abstracts, are as follows: Abstract titlePresenter / Lead authorPresentation detailsSPONSORED STUDIES Fruquintinib plus Sintilimab in Treated Advanced Endometrial Cancer (EMC) Patients (Pts) with pMMR Status: Results From a Multicenter, Single-Arm Phase 2 StudyXiaohua Wu, Fudan University Shanghai Cancer Center, Shanghai, China#5619Poster Session - Gynecologic CancerEfficacy and safety of fruquintinib in patients with metastatic colorectal cancer according to prior treatment sequence in the refractory setting: Results from FRESCO and FRESCO-2Tanios S. Bekaii-Saab, Mayo Clinic, U.S.#3579Poster Session - Gastrointestinal Cancer — Colorectal and AnalFruquintinib in Refractory Metastatic Colorectal CancerCathy Eng, Vanderbilt-Ingram Cancer Center, U.S.LinkEducation Session: New Drugs in Oncology: Incorporation Into PracticeUpdates on Abstract 438730: Fruquintinib Plus Paclitaxel Versus Paclitaxel as Second-Line Therapy for Patients with Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (FRUTIGA): A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Phase 3 StudyFeng Wang, Sun Yat-Sen University Cancer Center, Guangzhou, ChinaLinkEducation Session: ASCO Plenary Series: Rapid Abstract UpdatesSurufatinib plus PD-1/L1 inhibitors as maintenance therapy following first line (1L) platinum-based chemotherapy combined with PD-1/L1 inhibitors in patients (pts) with extensive-stage small cell lung cancer (ES-SCLC)Yi Hu,Chinese PLA General Hospital, Beijing, China#e15109Publication Only: Developmental Therapeutics — Molecularly Targeted Agents and Tumor BiologyFirst-in-human study of HMPL-295, an ERK1/2 inhibitor, in patients with advanced solid tumors: dose-escalation results of monotherapyXianjun Yu,Fudan University Shanghai Cancer Center, Shanghai, China#e15112Publication Only: Developmental Therapeutics—Molecularly Targeted Agents and Tumor BiologyINVESTIGATOR-INITIATED STUDIES Stereotactic ablative radiotherapy combined with fruquintinib and tislelizumab in metastatic colorectal cancer: updated findings from a single-arm, prospective phase II trial (RIFLE)Chen Yajie, Zhang Zhen,Fudan University Shanghai Cancer Center, Shanghai, China#e15570Publication Only: Gastrointestinal Cancer—Colorectal and AnalA propensity score matched comparison of fruquintinib (FRU) versus FRU combined with PD-1 inhibitors for microsatellite stability (MSS) metastatic colorectal cancer: real-world dataLina He, Shuiping Tu,Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China#e15564 Publication Only: Gastrointestinal Cancer—Colorectal and AnalPhase Ib/II trial of hepatic arterial infusion chemotherapy (HAIC) in combination with fruquintinib as third-line therapy for refractory unresectable colorectal cancer liver metastasesZhu Xu,Peking University Cancer Hospital and Institute, Beijing, China#3561Poster Session - Gastrointestinal Cancer—Colorectal and AnalEfficacy and safety of fruquintinib plus trifluridine/tipiracil (TAS-102) as third-line treatment in patients with metastatic colorectal adenocarcinoma: Results from a single arm, phase 2, multicenter studyJianjun Peng,The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China#3536Poster Session - Gastrointestinal Cancer — Colorectal and AnalA phase II study to evaluate the efficacy and safety of fruquintinib combined with tislelizumab and Hepatic arteryinfusion chemotherapy (HAIC) for advanced colorectal cancer liver metastases: An updated analysis of survivalLu Wang, Zhang Ti,Fudan University Shanghai Cancer Center, Shanghai, China#3543Poster Session - Gastrointestinal Cancer — Colorectal and AnalFruquintinib combined with sintilimab and SOX as conversion therapy for unresectable locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma (GC/GEJC): A single-arm, open-label, phase 2 clinical trialSuxia Luo, Fei Ma,Henan Cancer Hospital/Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, China#e16021Publication Only: Gastrointestinal Cancer — Gastroesophageal, Pancreatic, and HepatobiliaryShort-course radiotherapy (SCRT) followed by fruquintinib plus adebrelimab and CAPOX in the total neoadjuvant therapy of locally advanced rectal cancer (LARC): a multicenter, single-arm, open-label, phase II studyTao Zhang, Zhenyu Lin,Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, ChinaTPS3643Poster Session: Gastrointestinal Cancer — Colorectal and AnalFruquintinib plus capecitabine versus capecitabine as first-line maintenance treatment of metastatic colorectal cancer (mCRC): Update results from the randomized, controlled, phase Ib/II studyJunjie Peng, Wenhua Li,Fudan University Shanghai Cancer Center, Shanghai, China#3567Poster Session: Gastrointestinal Cancer — Colorectal and AnalEfficacy and safety of fruquintinib plus investigator's choice of chemotherapy as second-line therapy in metastatic colorectal cancer: updated results of a multicenter, single-arm, phase 2 trialYongshun Chen, Wensi Zhao,Renmin Hospital of Wuhan University, Wuhan, China#3571Poster Session: Gastrointestinal Cancer — Colorectal and AnalComparative analysis of first-line therapy with fruquintinib plus chemotherapy versus standard therapy in advanced metastatic colorectal cancer (mCRC): A prospective cohort study compared with propensity score matching (PSM) cohortFuxiang Zhou, Wenbo Wang,Zhongnan Hospital of Wuhan University, Wuhan, China#3591Poster Session: Gastrointestinal Cancer —Colorectal and AnalEfficacy and safety of fruquintinib-based treatment in patients with refractory bone and soft tissue sarcomas after developing resistance to several TKIs: A multi-centered retrospective studyLu Xie, Binghao Li,Peking University People’s Hospital, Beijing, China; The Second Affiliated Hospital Zhejiang University, Hangzhou, China#11528Poster Session: SarcomaDisitamab vedotin combined with fruquintinib in patients with HER2-expressing or HER2 mutation/amplified metastatic colorectal cancer refractory to at least two standard regimens: A prospective, exploratory, single-arm studyHui Xu,Zhongnan Hospital of Wuhan University. Wuhan, China#e15003Publication Only: Developmental Therapeutics — Molecularly Targeted Agents and Tumor BiologySurufatinib combined with TAS-102 in third- or later-line therapy of patients with metastatic pancreatic cancer (mPDAC): an open-Label, single-Arm, phase II StudyDongsheng Zhang,Sun Yat-sen University Cancer Center, Guangzhou, China#e16297Publication Only: Gastrointestinal Cancer — Gastroesophageal, Pancreatic, and HepatobiliarySurufatinib monotherapy or combined with vinorelbine as a late-line therapy in patients with refractory advanced non-small cell lung cancer (NSCLC)Yanfang Zheng,Affiliated Cancer Hospital and Institute of Guangzhou Medical University, Guangzhou, China#e20543Publication Only: Lung Cancer — Non-Small Cell MetastaticUpdated efficacy and safety results from the phase Ib/II study of surufatinib combined with camrelizumab and chemotherapy in patients with advanced colorectal cancerLiangjun Zhu, Sheng Li,Jiangsu Cancer Hospital, Nanjing, China#e15547Publication Only: Gastrointestinal Cancer — Colorectal and AnalPhase II study to evaluate surufatinib in patients with osteosarcoma and soft tissue sarcoma who have failed in standard chemotherapy: updated analysisXing Zhang,Sun Yat-sen University Cancer Center, Guangzhou, China#11539Poster Session: SarcomaEfficacy and safety of Surufatinib combined with EP regimen and Serplulimab in first-line treatment of NECTao Zhang, Zhenyu Lin,Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China#e15123Publication Only: Developmental Therapeutics — Molecularly Targeted Agents and Tumor BiologyPerformance of surufatinib in treating advanced neuroendocrine neoplasms: Insights from a real-world studyQing Zhai, Linhui Zhu,Fudan University Shanghai Cancer Center; Shanghai Medical College, Fudan University, Shanghai, China#e15124Publication Only: Developmental Therapeutics — Molecularly Targeted Agents and Tumor BiologyEpidemiological investigation of neuroendocrine differentiation in carcinomas: Focus on pancreatic and cholangiocarcinoma cohortsSusheng Shi, Yaru Wen,Cancer Hospital Chinese Academy of Medical Sciences, Beijing, China#e16375Publication Only: Gastrointestinal Cancer — Gastroesophageal, Pancreatic, and HepatobiliaryEfficacy and safety of surufatinib, toripalimab, nab-paclitaxel in combination with radiotherapy or surgery in the first-line treatment of esophageal squamous cell cancer: A single-centered prospective clinical trialFang Liu, Xiang Huang,Chinese PLA General Hospital, Beijing, China#e16047Publication Only: Gastrointestinal Cancer — Gastroesophageal, Pancreatic, and HepatobiliaryEfficacy and safety of second-line treatment with surufatinib for anlotinib-resistant radioiodine-refractory differentiated thyroid cancer: An exploratory multicenter studyLibo Chen, Yang Wang,Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China#e15127Publication Only: Developmental Therapeutics — Molecularly Targeted Agents and Tumor Biology About HUTCHMED HUTCHMED (Nasdaq/AIM:HCM; HKEX:13) is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery, global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. It has approximately 5,000 personnel across all its companies, at the center of which is a team of about 1,800 in oncology/immunology. Since inception, HUTCHMED has focused on bringing cancer drug candidates from in-house discovery to patients around the world, with its first three medicines marketed in China, the first of which is also marketed in the U.S. For more information, please visit: www.hutch-med.com or follow us on LinkedIn. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect HUTCHMED’s current expectations regarding future events, including but not limited to its expectations regarding the therapeutic potential of fruquintinib, surufatinib and HMPL-295, the further clinical development for fruquintinib, surufatinib and HMPL-295, its expectations as to whether any studies on fruquintinib, surufatinib and HMPL-295, would meet their primary or secondary endpoints, and its expectations as to the timing of the completion and the release of results from such studies. Such risks and uncertainties include, among other things, assumptions regarding enrollment rates and the timing and availability of subjects meeting a study’s inclusion and exclusion criteria; changes to clinical protocols or regulatory requirements; unexpected adverse events or safety issues; the ability of fruquintinib, surufatinib and HMPL-295, including as combination therapies, to meet the primary or secondary endpoint of a study, to obtain regulatory approval in different jurisdictions and to gain commercial acceptance after obtaining regulatory approval; the potential markets of fruquintinib, surufatinib and HMPL-295 for a targeted indication, and the sufficiency of funding. In addition, as certain studies rely on the use of nab-paclitaxel, sintilimab, toripalimab, pemetrexed, platinum, etoposide or cisplatin as combination therapeutics, such risks and uncertainties include assumptions regarding their safety, efficacy, supply and continued regulatory approval. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. For further discussion of these and other risks, see HUTCHMED’s filings with the U.S. Securities and Exchange Commission, The Stock Exchange of Hong Kong Limited and on AIM. HUTCHMED undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise. Medical Information This press release contains information about products that may not be available in all countries, or may be available under different trademarks, for different indications, in different dosages, or in different strengths. Nothing contained herein should be considered a solicitation, promotion or advertisement for any prescription drugs including the ones under development. CONTACTS Investor Enquiries+852 2121 8200 / ir@hutch-med.com Media Enquiries Ben Atwell / Alex Shaw, FTI Consulting+44 20 3727 1030 / +44 7771 913 902 (Mobile) / +44 7779 545 055 (Mobile) / HUTCHMED@fticonsulting.comZhou Yi, Brunswick+852 9783 6894 (Mobile) / HUTCHMED@brunswickgroup.com Nominated Advisor Atholl Tweedie / Freddy Crossley / Daphne Zhang, Panmure Gordon+44 (20) 7886 2500

Phase 2Clinical ResultPhase 3ASCONDA

100 Deals associated with Adebrelimab

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	-	DB16412

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Extensive stage Small Cell Lung Cancer	CN	Shanghai Shengdi Pharmaceutical Co., Ltd.	28 Feb 2023

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Advanced Hepatocellular Carcinoma	Phase 3	CN	Suzhou Suncadia Biopharmaceuticals Co., Ltd.	28 Oct 2024
Non-squamous non-small cell lung cancer	Phase 3	CN	Shanghai Shengdi Pharmaceutical Co., Ltd.	29 Mar 2024
Non-squamous non-small cell lung cancer	Phase 3	CN	Suzhou Suncadia Biopharmaceuticals Co., Ltd.	29 Mar 2024
Small Cell Lung Cancer	Phase 3	CN	Jiangsu Hengrui Pharmaceuticals Co., Ltd.	20 Jan 2021
Non-small cell lung cancer stage IIIB	Phase 3	CN	Jiangsu Hengrui Pharmaceuticals Co., Ltd.	14 Jul 2020
Resectable Lung Non-Small Cell Carcinoma	Phase 3	CN	Jiangsu Hengrui Pharmaceuticals Co., Ltd.	10 Jul 2020
Locally Advanced Lung Non-Small Cell Carcinoma	Phase 2	CN	Shanghai Hengrui Pharmaceutical Co., Ltd.	27 Sep 2024
HR-negative/HER2-low Breast Carcinoma	Phase 2	CN	Suzhou Suncadia Biopharmaceuticals Co., Ltd.	20 Sep 2024
HR-positive/HER2-low Breast Carcinoma	Phase 2	CN	Jiangsu Hengrui Pharmaceuticals Co., Ltd.	23 Aug 2024
Hormone receptor positive HER2 negative breast cancer	Phase 2	-	Jiangsu Hengrui Pharmaceuticals Co., Ltd.	01 Aug 2024

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ADBL-LC-001 (ESMO_IO2024) Manual	Not Applicable	Small Cell Lung Cancer First line	143	Adebrelimab (ES-SCLC)	emuxoflcuj(dyfcuhtdul) = kjpidmynae jjayemdyzl (rbdfezeano, 10.0 - 14.9) View more	Positive	12 Dec 2024
ADBL-LC-001 (ESMO_IO2024) Manual	Not Applicable	Small Cell Lung Cancer First line	143	Adebrelimab (LS-SCLC)	emuxoflcuj(dyfcuhtdul) = yggzgzrrwq jjayemdyzl (rbdfezeano, 13.7 - NA) View more	Positive	12 Dec 2024
ESMO_IO2024 Manual	Not Applicable	Extensive stage Small Cell Lung Cancer First line	188	Adebrelimab-based regimen	lugwywflbr(lwwlabpmze) = bduzfvbbrm rkaerxmbdd (mfteqajied ) View more	Positive	12 Dec 2024
NCT06198465 (ESMO_IO2024) Manual	Phase 2	Gastroesophageal junction adenocarcinoma Neoadjuvant	15	Adebrelimab + nab-paclitaxel + lobaplatin + S-1	uxjidrvufr(hmhwlpsyif) = dhjveuzhbi sffdwwkmbk (xjgbnzpkbm ) View more	Positive	12 Dec 2024
NCT04562337 (Pubmed \| EClinicalMedicine) Manual	Phase 2	Extensive stage Small Cell Lung Cancer First line	67	Adebrelimab + EP/EC chemotherapy	kiaxwkypbc(wvdmlgnxps) = xigzxrqvcy chuzdcvopg (uvpdasvfcd, 17.2 - NR) View more	Positive	01 Sep 2024
NCT04562337 (CAPSTONE-1, ASCO2024) Manual	Phase 3	Extensive stage Small Cell Lung Cancer Maintenance	67	Adebrelimab + EP/EC + TRT	tcxvtixkem(kntxrcndja) = vjfatncjul yhgtztyblv (sjwufjthku, 17.2 - not reached) View more	Positive	24 May 2024
ESMO_ELCC2024	Phase 3	Small cell lung cancer limited stage \| Small Cell Lung Cancer	28	Adebrelimab + carboplatin + etoposide + thoracic radiotherapy	fgouqiikrw(hcpbynovqf) = tjbefdqwpq nmvsqubuto (ivonuzvilr, 87.7 - 100) View more	-	22 Mar 2024
NCT04691063 (ESMO_ELCC2024) Manual	Phase 3	Small Cell Lung Cancer	28	Adebrelimab + carboplatin + etoposide + thoracic radiotherapy	jbbuaxfxbf(ylkjxprhrl) = djfjndunrg jnetxrqpda (wpqmlroiye ) View more	Positive	20 Mar 2024
CAPSTONE-1 (ESMO_IO2023)	Phase 3	Extensive stage Small Cell Lung Cancer First line	462	Adebrelimab	elwueuiubz(uirpuqqres) = hyafwdthsj tydtabpboj (peildalarl, 13.2 - 17.3)	Positive	07 Dec 2023
CAPSTONE-1 (ESMO_IO2023)	Phase 3	Extensive stage Small Cell Lung Cancer First line	462	Placebo	elwueuiubz(uirpuqqres) = qucdjgwwjy tydtabpboj (peildalarl, 11.3 - 13.9)	Positive	07 Dec 2023
NCT04215471 (Pubmed) Manual	Phase 1	Esophageal Squamous Cell Carcinoma Neoadjuvant	30	adebrelimab	ixacsstjov(ebqmnphrnt) = Common treatment-related adverse events were anorexia (32%) and fatigue (16%), without grade 3 or more adverse events. mrogebijnf (uggdywzsko )	Positive	24 Jul 2023
NCT04562337 (ASCO 12023 \| ASCO 22023) Manual	Phase 2	Extensive stage Small Cell Lung Cancer First line	63	chemotherapy+sequential chest radiotherapy+SHR-1316	tavwrgwcsj(bakrgrfyte) = dhgcbexeam kfytfvzlnl (yqlcjqzzmq, 4.3 - 9.7) View more	Positive	26 May 2023

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis